G protein-coupled receptors (GPCRs) are the major class of sensory proteins and a primary therapeutic target in the pathways to pain and itch. GPCRs are complex signaling machines. Their association with ligands, other receptors, and signaling and regulatory partners induces GPCRs to adopt distinct conformations and to traffic to microdomains within plasma and endosomal membranes. This conformational and positional dynamism controls GPCR signaling in time and space and defines the outcome of receptor activation. An understanding of the dynamic nature of GPCRs within primary sensory neurons and neighboring cells brings new insights into their contributions to the physiology and pathophysiology of pain and itch and provides novel opportunities for therapeutic intervention.
Introduction
With approximately 850 members, G protein-coupled receptors (GPCRs) are the largest family of signaling proteins. GPCRs enable cells to detect structurally diverse agonists, including most hormones, neurotransmitters, and paracrine agents, as well as photons, odorants, and tastants. Given the size of this family, their ubiquitous expression, and the diversity of their agonists, it is not surprising that GPCRs participate in most physiological and pathophysiological processes and are a major target for therapy.
GPCRs are complex signaling machines. Much of this complexity is due to their conformational and positional dynamism ( Figure 1 ). All GPCRs comprise seven a-helical transmembrane domains, an extracellular N terminus with three extracellular loops, and an intracellular C terminus with three intracellular loops. GPCRs are not rigid switches that exist in ''off'' (unbound) and ''on'' (agonist-bound) conformations. Instead, they can adopt a series of fleeting conformations that are influenced by association with ligands, other receptors, signaling and regulatory proteins, by post-translational modifications, and by environmental cues. This conformational flexibility determines the capacity of receptors to engage with signaling machinery. It may explain how ligands that interact with binding sites that are distinct from those occupied by endogenous ligands can alter receptor function (allosteric modulation, Figure 1A ), and how different ligands of the same receptor can preferentially activate certain signaling pathways (signaling bias, Figure 1B ). Changes in conformation are also likely to determine how interactions between two different receptor molecules can influence their function (receptor oligomerization, Figure 1C ) and account for the ability of certain GPCRs to become active in the absence of ligand (constitutive activity, Figure 1D ). The dynamic nature of GPCRs is further illustrated by the trafficking of activated receptors from the cell surface to the endosomal network. Agonist-stimulated trafficking enables GPCRs to assemble signaling complexes in subcellular compartments, which can lead to unique downstream outcomes (compartmentalized signaling) ( Figure 1E ). Variants of receptors that are produced by alternate mRNA splicing exhibit altered conformation and trafficking, which adds further complexity.
GPCRs are the largest class of sensory proteins and are important therapeutic targets in the pathways to pain and itch ( Figure 2 ). Pseudounipolar primary sensory neurons of dorsal root, trigeminal, and vagal ganglia, also known as nociceptors and pruritoceptors, are the first cells in these pathways. The peripheral endings of these neurons are equipped with GPCRs that sense structurally diverse stimulants and inhibitors of neuronal activity. Second-order spinal neurons also express GPCRs for transmitters released from the central endings of primary sensory neurons and from other spinal neurons. Second-order neurons integrate signals and transmit pain and itch to the brain. During disease, there are remarkable changes in the levels and types of GPCRs that are expressed by primary sensory neurons and their targets, which further illustrates the dynamic nature of this system. Herein, we discuss the conformational and positional dynamism of GPCRs that control pain and itch. We highlight the importance of allosteric modulation, biased agonism, receptor oligomerization, constitutive activity, and trafficking-dependent signaling for pain and itch transmission, and therapeutic intervention. We illustrate these processes by discussing selected GPCRs of primary sensory and spinal neurons. We refer readers to comprehensive reviews of the mechanisms of pain and itch Bautista et al., 2014) . peptides (kinins, tachykinins, opioids), purines and nucleotides (adenosine, ATP), lipids (prostaglandins), steroids (bile acids), and proteases (serine and cysteine) (Figure 2A ).
Histamine and 5-hydroxytryptamine (5-HT) are prominent stimulants of pain and itch. In common with many agonists, histamine and 5-HT can activate several receptor subtypes, sometimes with different outcomes. Histamine causes pain and itch by activating histamine 1 receptors (H 1 R) on cutaneous afferent nerves (Rosa and Fantozzi, 2013) . 5-HT enhances excitability of primary sensory nerves to evoke hyperalgesia and scratching by activating 5-HT 2B R and 5-HT 7 R (Cardenas et al., 1999; Lin et al., 2011; Morita et al., 2015) . However, activation of the inhibitory Ga i -linked H 3 R suppresses the release of sensory neuropeptides and dampens pain transmission (Geppetti et al., 2012; Hough and Rice, 2011) .
Bradykinin, generated during injury and inflammation by the action of kallikreins on kininogens, is the prototype algesic peptide of inflammatory exudates. Bradykinin induces acute nociceptive behavior by activating the B 2 R on sensory nerves, whereas the B 1 R plays a more prominent role during persistent pain (Peth} o and Reeh, 2012) . The m, d, and k opioid receptors (MOR, DOR, and KOR) are the most extensively studied antinociceptive GPCRs and a therapeutic target for pain. DOR and MOR are expressed by primary sensory neurons where activation inhibits hypersensitivity . DOR is expressed by cutaneous mechanoreceptors, and DOR activation on the central terminals of mechanoreceptors suppresses synaptic input to the dorsal horn, suggesting that DOR is a target for injury-evoked mechanical hypersensitivity (Bardoni et al., 2014) . During inflammation opioids from immune cells can activate ORs of primary sensory nerves and may thereby inhibit inflammatory pain (Boué et al., 2014) .
Injury and inflammation result in the activation of a large number of serine and cysteine proteases that derive from the circulation (coagulation factors), immune cells (mast cell tryptase, macrophage cathepsin S, neutrophil elastase), and epithelial tissues (trypsin IV, kallikreins). These proteases can regulate primary sensory nerves by cleaving protease-activated receptor-2 (PAR 2 ). PAR 2 agonists excite or sensitize sensory neurons to promote neurogenic inflammation (Steinhoff et al., 2000) , pain (Vergnolle et al., 2001) , and itch (Reddy et al., 2008; Steinhoff et al., 2003) .
Members of the large family of Mas-related GPCRs (Mrgprs) are expressed by primary sensory neurons and are important mediators of pain and itch (Dong et al., 2001) . The antimalarial drug chloroquine, which causes severe itch that can limit compliance, induces MrgprA3-dependent scratching in mice (Liu et al., 2009 ). Bovine adrenal medulla peptide [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , a product of proenkephalin A, activates MrgrpC11 in mice to induce itch (Liu et al., 2009 ). Mice lacking a cluster of Mrgprs genes, notably MrgprA3 and MrgprC11, display exaggerated inflammatory hyperalgesia yet normal neuropathic hypersensitivity, indicating that certain Mrgprs can inhibit inflammatory pain (Guan et al., 2010) .
GPCRs of Second Order Spinal Neurons
Prominent transmitters released from the central projections of primary spinal afferent neurons include glutamate, substance P (SP), and calcitonin gene-related peptide (CGRP), which activate GPCRs of dorsal spinal neurons ( Figure 2B ). For example, noxious peripheral stimuli trigger SP release in the dorsal horn and subsequent activation and endocytosis of the neurokinin 1 receptor (NK 1 R) (Mantyh et al., 1995) . Neuropeptides from intrinsic neurons, including the analgesic opioids, can also regulate the activity of second order spinal neurons that transmit pain and itch. Gastrin-releasing peptide (GRP), the mammalian homolog of the amphibian skin peptide bombesin, is an itch-selective transmitter in the spinal cord (Sun and Chen, 2007) . There has been considerable controversy about whether GRP originates from primary sensory or spinal neurons, although studies using in situ hybridization, immunofluorescence, and a GRPeGFP reporter mouse suggest that spinal interneurons are the primary source (Solorzano et al., 2015) . Whereas GRP released within the spinal cord can activate spinal neurons expressing the GRP receptor to evoke itch, dynorphin, which derives from a population of spinal inhibitory interneurons, activates KOR within the spinal cord to suppress itch (Kardon et al., 2014) .
The GPCR-TRP Channel Axis: Partners on the Pathways to Pain and Itch
The capacity of GPCRs to excite primary sensory neurons requires activation of transient receptor potential (TRP) ion channels (Figure 3 ). Although the 28 member TRP family is dwarfed by the GPCR superfamily, the activities of many GPCRs converge on a small number of TRP channels, which are vitally important for sensory signaling (reviewed in Veldhuis et al., 2015) . Members of the TRP vanilloid (TRPV1, TRPV2, TRPV3, TRPV4), TRP melastatin (TRPM2, TRPM8), and TRP ankyrin (TRPA1) subfamilies are downstream effectors of GPCR nociceptive and pruritogenic signaling.
TRPs are non-selective cation channels of four identical or similar subunits, each with six transmembrane domains and (McNeil et al., 2015) . CGRP activates calcitonin receptor-like receptor and receptor activity modifying protein 1 (CLR/RAMP1) on arterioles to cause vasodilation and hyperemia. (C) Central transmission. Central terminals of primary sensory neurons release glutamate, SP, and CGRP, which activate their GPCRs on spinal neurons to promote central transmission.
Neuron 88, November 18, 2015 ª2015 Elsevier Inc. 637 Neuron Review intracellular N and C termini. The transmembrane and extracellular pore domains are sensitive to environmental cues, including temperature and pH (TRPV1), mechanical stimuli (TRPV4), reactive oxygen species (TRPA1), and direct stimulation by natural products, such as capsaicin from chilies (TRPV1), allyl isothiocyanate from horseradish (TRPA1), and menthol from mint (TRPM8). In addition to these direct mechanisms of activation, the membrane-spanning and intracellular regions of TRPs can undergo post-translational modification and bind to signaling messengers, which both mediate GPCR-stimulated channel activity. The concept that TRPs are ''receptor-operated channels'' was originally observed in Drosophila melanogaster, where TRP mutants displayed diminished responses to the GPCR rhodopsin (Hardie and Raghu, 2001) . 3.1. Mechanistic Basis of the GPCR-TRP Axis GPCRs can stimulate TRPs by two general mechanisms: Ga-mediated activation of phospholipases (e.g., PLCb, PLA 2 ) that relieve phosphatidylinositol 4,5-bisphosphate (PIP 2 )-dependent channel inhibition and generate endogenous TRP agonists, and stimulation of kinases (protein kinase (PK)C, PKA, tyrosine kinases) that phosphorylate TRPs to increase cell-surface expression and interactions with adaptor proteins (Veldhuis et al., 2015) (Figure 3 ). These mechanisms lead to TRP channel sensitization (i.e., increase TRP sensitivity to non-noxious stimuli) or activation. (Veldhuis et al., 2015) . The GPCR-TRP axis also contributes to itch. Whereas TRPV1 is implicated in histamine-dependent itch, TRPA1 mediates histamine-independent itch (Bautista et al., 2014) . Histamine/H 1 R activate TRPV1 in sensory nerves by PLC/PKC-and PLA 2 /lipoxygenase-pathways, leading to scratching in mice (Kim et al., 2004; Shim et al., 2007) . Several pruritogenic GPCRs cause TRPA1-dependent excitation of sensory nerves and scratching in mice, albeit by divergent signaling mechanisms. Whereas the pruritogenic actions of chloroquine involve MrgprA3-and Gbg-dependent activation of TRPA1, the effects of Bam8-22 involve MrgC11-and PLCb-dependent activation of TRPA1 (Wilson et al., 2011 (Wilson et al., , 2013a . The bile acid receptor TGR5 is a potential mediator of pruritus in patients with cholestatic liver disease and increased circulating levels of bile acids (Alemi et al., 2013) . TGR5 induces Gbg-and PKC-mediated activation of TRPA1 in cutaneous afferent neurons, leading to release of the pruritogenic neuropeptides GRP and natriuretic polypeptide B, activation of spinal neurons, and scratching . Sequestration of bile acids and antagonism of TRPA1 ameliorate spontaneous scratching in Tgr5 transgenic mice, which suggests TGR5-mediated activation of TRPA1 is pathophysiologically important.
Proteases that activate PAR 2 can evoke a TRPA1-dependent itch in mice by a complex mechanism that involves keratinocytes, immune cells, and sensory nerves. Proteases that activate PAR 2 in the epidermis stimulate the production of itch-inducing cytokines, including thymic stromal lymphopoietin (TSLP), from keratinocytes (Moniaga et al., 2013) . TLSP, a chemoattractant for immune cells, activates TLSP chemokine receptor signaling and TRPA1 activity on sensory neurons to induce scratching (Wilson et al., 2013b) . Mediators released from epithelial cells in multiple tissues may similarly activate sensory nerves to induce pain and itch.
Allosteric Modulators of GPCRs: Pathways to Subtlety
Allostery, from the Greek for other (allos) site (stereos), refers to the capacity of a ligand to interact with a protein at a site that is distinct from the binding site for endogenous ligands or substrates. Allosteric modulators alter the conformation of proteins GPCRs activate multiple pathways that converge on TRP channels. Ga q protein signaling (green) stimulates PLA 2 to produce arachidonic acid (AA) and downstream polyunsaturated fatty acid (PUFA) endogenous TRP channel ligands via LOX, cytochrome P450, and COX activity. PLC metabolizes PIP 2 to produce DAG, IP 3 , and intracellular Ca 2+ release, increasing PKC kinase activity and TRP channel phosphorylation. Ga s protein signaling (red) stimulates adenylate cyclase (AC) activity; cAMP production and PKA activity promote TRP channel phosphorylation and sensitization. Together, these pathways increase the likelihood of TRP channels responding to endogenous stimuli. Conversely, Ga i/o signaling (purple) promotes analgesia through inhibition of AC-dependent cAMP formation. Gbg proteins (blue) activate TRPA1 and cause itch through pathways that are yet to be characterized in detail. TRP channel activity stimulates voltage-gated ion flux, membrane depolarization and downstream action potentials (AP) for central transmission of pain or itch. Stimulated primary afferent terminals also release peptides in the periphery (e.g., SP, CGRP) to mediate itch and neurogenic inflammation. Figure 1A ). Allosteric drugs offer increased opportunity for receptor subtype selectivity, since allosteric sites are less likely than orthosteric sites to be conserved between GPCR subtypes. By modulating responses to endogenous agonists, allosteric drugs may allow ''fine-tuning'' of regulatory processes. However, little is known about the structural basis of allosteric modulation of GPCRs, which hinders rational drug design, although recent advances in GPCR structural biology are beginning to address this issue. Moreover, allosteric drugs can be species specific, due to the lack of evolutionary pressure to conserve allosteric sites. There are currently two approved allosteric modulators of GPCRs (cinacalcet, a calcium-sensing receptor PAM for hyperparathyroidism; maraviroc, a chemokine receptor 5 NAM for HIV). Although both drugs were found to be allosteric modulators ex post facto, there remains a sustained interest in developing allosteric modulators of GPCRs for pain (Nickols and Conn, 2014) .
Structural Basis of Allosteric Modulation
Structural studies of family A (rhodopsin-like) GPCRs show that transmembrane and extracellular domains accommodate orthosteric ligands. Little is known about the structural basis of allosteric modulation of GPCRs. A notable exception is the b 2 -adrenergic receptor (b 2 AR), where G protein association promotes high-affinity binding of an orthosteric ligand (Rasmussen et al., 2011) . Here, a network of conformational changes connect the orthosteric ligand binding site and the allosteric G protein binding site at the intracellular face of the receptor. Observations of the muscarinic M2 receptor bound to an orthosteric agonist and a small molecule PAM indicate the presence of an extracellular vestibule for allosteric modulators that is pre-formed in the presence of agonist (Kruse et al., 2013) .
PAMs for Pain
The identification of allosteric drugs that amplify the anti-nociceptive effects of GPCR ligands is an attractive strategy for ''dialing down'' pain. A rationale for developing such drugs is that the usefulness of orthosteric agonists is often limited by side effects, and PAMs that amplify or bias the actions of endogenous ligands may allow for more subtle control. For example, MOR PAMs would be expected to enhance the analgesic activity of endogenous opioids or MOR agonists. However, since MOR mediates the beneficial analgesic actions of opioids, as well as the detrimental effects of dependence, respiratory depression, and constipation, there is no a priori reason why PAMs would be expected to have an improved therapeutic profile unless there is also an element of bias in their allosteric effects (Kenakin and Christopoulos, 2013) . MOR PAMs have been identified that enhance b-arrestin recruitment and cAMP inhibition induced by the orthosteric agonist endomorphin-I (Burford et al., 2013) . Their effects may be related to interference with the interaction between MOR and Na + ions, endogenous NAMs that stabilize inactive receptors (Livingston and Traynor, 2014) . PAMs for metabotropic gamma-amino-n-butyric acid (GABA) B receptors are also attractive given the anti-nociceptive actions of these receptors in chronic but not acute pain (Hanack et al., 2015) . Studies of selectivity and efficacy in preclinical models are required to determine whether PAMs of analgesic GPCRs are useful treatments for pain.
NAMs for Pain
NAMs that attenuate the activation of pro-nociceptive GPCRs by endogenous agonists offer the possibility of more subtle suppression of pain than could be achieved by competitive inhibitors. The rational design of a small molecule allosteric inhibitor of the C5a receptor (C5aR) illustrates the potential of this approach (Moriconi et al., 2014) . C5a, an anaphylatoxin peptide generated during complement activation, signals to the C5aR on primary sensory neurons, spinal microglial cells, and immune cells to induce inflammatory and neuropathic pain. Although C5aR is an attractive target, orthosteric antagonists lack selectivity and potency, or have poor bioavailability and short halflife (Griffin et al., 2007; Moriconi et al., 2014) . A selective and non-competitive allosteric inhibitor of C5aR suppresses mechanical hyperalgesia in acute and chronic models of inflammatory and neuropathic pain in mice, yet lacks anti-nociceptive activity in C5aR knockout mice, which confirms specificity.
The Janus Face of GPCRs: Pathways to Biased Agonism
In a manner that is reminiscent of Janus, the Roman god of transitions, GPCRs translate extracellular cues into intracellular signals. A common feature of GPCRs is the existence of several ligands of the same receptor. Based on the assumption that agonists would all stabilize a single active conformation of the receptor, the prevailing view was that individual GPCRs would activate the same signaling events. However, it is now clear that different agonists can selectively stabilize unique conformations that favor receptor coupling to particular signaling pathways (i.e., biased agonism, reviewed in Kenakin and Christopoulos, 2013) ( Figure 1B ). Thus, like Janus, a god with two faces, GPCRs can adopt distinct conformations that dictate their activation of various signaling pathways. Biased agonism may allow different endogenous agonists of the same receptor to exert distinct physiological effects, although this possibility has not been thoroughly evaluated. Biased agonism also holds the tantalizing prospect of developing ''designer agonists'' that would be biased toward the activation of therapeutically beneficial pathways at the expense of those that underlie detrimental side effects. There are formidable challenges in understanding the importance of biased agonism, particularly in vivo (reviewed in Zhou and Bohn, 2014 ). An understanding of the relevance of biased agonism is hampered by the paucity of information about the signaling events that underlie the actions of endogenous agonists and drugs. The attribution of different actions of agonists in vivo to biased agonism is fraught with problems. Differences in the metabolic stability, tissue penetrance, duration of association with receptors, rather than biased agonism, may all explain differential effects of agonists. Off-target effects of agonists or their metabolites on other GPCRs or unrelated proteins may also give rise to the artifactual appearance of biased agonism. Although the capacity of different agonists to stabilize unique receptor conformations is thought to underlie biased agonism, such information exists for only a few GPCRs. Differences in the duration of interaction between ligands and receptors may also account for apparent biased agonism (reviewed in Hoffmann et al., 2015) .
Structural Basis of Biased Agonism
Structural studies of GPCRs are beginning to provide insights into biased signaling. The ability of agonists to differentially regulate b 2 AR signaling depends on their capacity to influence the conformation of helix VI for G protein bias or helix VII for b-arrestin bias . Studies of the b 2 AR bound to b-arrestin-biased ligands provide further insight (Warne et al., 2012) . Ergotamine, a treatment for migraine pain and a precursor of the hallucinogen lysergic acid, is a biased agonist of b-arrestin signaling of the 5-HT 2B R (hallucinogen action) but is an unbiased agonist of the 5-HT 1B R (antimigraine action) (Wacker et al., 2013) . Given the emerging importance of b-arrestin in mediating the therapeutic and adverse actions of certain drugs, such structural insights may be important for drug development.
Biased Agonism of Opioid Receptors
Although MOR agonists, such as morphine, oxycodone, and fentanyl, are widely used analgesics, their usefulness is limited by analgesic tolerance and side effects. Is it possible that different signaling pathways underlie the beneficial and detrimental actions of MOR, and could ''designer analgesics'' favor the beneficial over the detrimental pathways? This prospect has generated numerous studies of MOR signaling and trafficking and of the relevance of biased agonism for analgesia, tolerance, and side effects (reviewed in Williams et al., 2013) .
Studies of b-arrestin-2-deficient mice have revealed differential roles of b-arrestin-2 in analgesia, tolerance, and the side effects of MOR agonists. Whereas b-arrestin-2 inhibits anti-nociceptive signaling of MOR (Bohn et al., 1999) , it mediates MOR signaling that underlies the unwanted side effects of morphine (Raehal et al., 2005) . These findings provided the impetus to seek MOR agonists that display biased signaling toward G protein pathways that mediate analgesia and away from b-arrestin-2 signaling pathways that are responsible for side effects. TRV130 is a synthetic MOR agonist with G protein-coupling efficacy similar to morphine and DAMGO, yet with reduced efficacy for b-arrestin-2 recruitment (DeWire et al., 2013) . Consistent with its reduced ability to recruit b-arrestin-2, TRV130 minimally stimulates MOR phosphorylation or internalization and retains analgesic activity in rodents, with reduced constipation and respiratory depression. In healthy men, TRV130 produced greater analgesia than morphine with a smaller reduction in respiratory drive and less nausea (Soergel et al., 2014 ).
An alternative to using biased agonists of MOR to improve pain treatment has been to target MOR variants. The MOR gene Oprm1 generates multiple splice variants, some of which encode a version of MOR with 6 transmembrane domains (mMOR-1G). 3-iodobenzoyl-6b-naltrexamide causes mMOR-1G-dependent analgesia in mice, without the side effects of respiratory depression and dependence (Lu et al., 2015) . Although mMOR-1G may be a viable therapeutic target, further studies are required to define the importance of GPCR variants in pain and itch.
Biased Agonism of Protease-Activated Receptors
Whereas the functional selectivity of most agonists results from reversible receptor binding, biased agonism of PARs arises from irreversible proteolysis, which leads to distinctly different pathways of receptor signaling and trafficking and divergent mechanisms of pain (reviewed in Zhao et al., 2014b) (Figure 4) . Trypsin, tryptase, and kallikrein cleave PAR 2 at the canonical R 36 YS 37 site, which exposes a tethered ligand that binds and activates the cleaved receptor. Trypsin-cleaved PAR 2 couples to Ga q/11 , second messenger kinases, and b-arrestins (Amadesi et al., 2006; Ayoub and Pin, 2013; DeFea et al., 2000b) . PAR 2 sensitizes TRPV1 (Amadesi et al., 2004) , TRPV4 , and TRPA1 (Dai et al., 2007) by mechanisms that include channel phosphorylation, synthesis of endogenous agonists, and release of PIP 2 -mediated inhibition. In contrast, cathepsin S (from macrophages, spinal microglial cells) and elastase (neutrophils, leukocytes) cleave PAR 2 at distinct sites, leading to divergent pathways of receptor signaling, trafficking, and TRP channel activation (Zhao et al., 2014a (Zhao et al., , 2015 . Thus, PAR 2 can integrate the actions of diverse proteases. The report that cathepsin S can also activate MrgprC11 to cause itch adds to the complexity of protease signaling to sensory nerves (Reddy et al., 2015) .
Oligomerization of GPCRs: Pathways to Diversity
Many receptors, including receptor tyrosine kinases and toll-like receptors, function as oligomers. The assembly of homodimers (2 identical receptors), heterodimers (2 different receptors), or multimers (>2 receptors) can influence ligand recognition, activation, signal transduction, and trafficking of these receptors and is thus essential for their normal function ( Figure 1C ). Whether GPCRs also interact with one another has been a topic of interest and controversy (reviewed in Ferré et al., 2014) . This controversy has led to the adoption of stringent criteria that are necessary to establish the existence of GPCR oligomerization. They include the demonstration that both receptors physically associate in native tissues or primary cells, identification of a key functional property of the receptor oligomer, and studies of animals in which one component of the complex is deleted or downregulated (Pin et al., 2007) . If GPCR dimers are to be considered therapeutic targets, it is also important to study colocalization and dimerization in diseased states, where the patterns of expression and subcellular localization of receptors can be markedly altered.
Oligomerization of Family C GPCRs
The strongest evidence for GPCR dimerization comes from the family C GPCRs, which include receptors for excitatory (glutamate) and inhibitory (GABA) neurotransmitters of pain pathways. Family C GPCRs possess a large extracellular N terminus, which contains multiple cysteine residues and a ligand binding Venus flytrap domain. Disulphide linkage between extracellular domains stabilize homodimers of metabotropic glutamate receptors (mGluRs) (Romano et al., 1996) . Dimerization allosterically couples the Venus flytrap and heptahelical domains and is necessary for ligand binding and G protein coupling (Tsuchiya et al., 2002) . Homodimerization of mGluRs is likely to be necessary for pain transmission. mGluR1 and mGluR5 are expressed by primary sensory neurons and spinal neurons, and antagonists of these receptors suppress pain (Goudet et al., 2009 ). Heterodimerization of GABA B1 and GABA B2 receptors masks an endoplasmic retention motif of the GABA B1 subunit and thereby facilitates plasma membrane trafficking (Margeta-Mitrovic et al., 2000) . Agonist binding to the GABA B1 component allosterically activates GABA B2 , which mediates signal transduction (Galvez et al., 2001) . GABA B1 knockout mice fail to respond to exogenous GABA B agonists and exhibit hyperalgesia due to absence of the normal tonic inhibitory activity of GABA in the dorsal horn, which illustrates the importance of this component of the dimer for normal receptor functions (Schuler et al., 2001 ). The relevance of GABA B dimerization for pain is illustrated by the finding that disruption of dimerization, by negating the tonic inhibitory actions of GABA in the dorsal horn, exacerbates pain (Laffray et al., 2012) .
Opioid Receptor Homo-and Hetero-dimers
Studies of single monomers of detergent-solubilized MOR reconstituted with Ga i2 in lipid vesicles show that this receptor can function as a monomer but do not exclude the possibility that it also functions as an oligomer (Kuszak et al., 2009 ). Indeed, MOR in complex with the antagonist b-funaltreaxamine crystallizes as a symmetrical dimer . A dimeric interface has also been identified from structural studies of KOR bound to the antagonist JDTic (Wu et al., 2012) . In contrast, a similar dimeric interface was not observed in crystals of DOR (Gomes et al., 2004; Gupta et al., 2010) . However, a prerequisite for dimerization is that MOR and DOR are colocalized not only in the same neuron but also within the same membrane microdomains. In some cases, this information is lacking or controversial. The association of these receptors has been questioned by the report that immunoreactive MOR and DOR-eGFP are largely expressed by different populations of peptidergic (MOR) and non-peptidergic (DOR) neurons of mouse dorsal root ganglia that separately control thermal (MOR) and mechanical (DOR) nociception . Although a subsequent study of DOR-eGFP and MOR-mCherry double knockin mice found that a more substantial proportion of neurons coexpress these receptors (Erbs et al., 2015) , these results are at odds with other reports showing extensive overlap (Wang et al., 2010) . Different methodologies may account for reported variability in the coexpression of these (and other) GPCRs.
After chronic use, the analgesic actions of morphine and fentanyl, which are mediated by MOR, are limited by tolerance. The MOR-DOR heteromer has been proposed to mediate analgesia and tolerance and to represent a target for analgesics with reduced tolerance. DOR disruption can enhance MOR-dependent analgesia and diminish tolerance, which suggests that DOR suppresses MOR activity and mediates tolerance (Zhu et al., 1999) . This inhibitory action of DOR may be related to alterations in post-endocytic sorting of MOR-DOR heteromers. Once internalized, MOR recycles and DOR traffics to lysosomes. However, DOR agonists promote internalization and degradation of both components of the MOR-DOR heteromer, which could diminish cell-surface MOR expression and contribute to tolerance (He et al., 2011) . Peptides that interfere with assembly of heteromers enhance morphine analgesia and attenuate tolerance, which supports this concept. Bivalent ligands based on the MOR agonist oxymorphone and the DOR antagonist naltrindole linked by spacer have anti-nociceptive activity and diminished tolerance (Daniels et al., 2005) . Only those ligands with an appropriate spacer length did not produce tolerance, which supports the view that they target the MOR-DOR heteromer. The therapeutic utility of bifunctional drugs is illustrated by finding that Eluxadoline, a molecule with MOR agonist and DOR antagonist activity, relieves abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (Dove et al., 2013) . Eluxadoline is now approved for treatment of diarrhea-predominant irritable bowel syndrome. Recent structural studies of ORs in complex with such bivalent drugs may facilitate the rational design of improved analgesics (Fenalti et al., 2015) .
Heterodimerization of Opioid Receptors with Other GPCRs
Although the intrathecal administration of morphine is an effective treatment for severe pain that can restrict some of the side effects of systemic administration, its usefulness is often limited by severe pruritus. Studies in mice suggest that a heterodimer of a splice variant of MOR, MOR1D, and the GRP receptor mediate morphine-induced scratching, whereas the MOR1 form of the receptor mediates morphine-induced analgesia . Peptides that disrupt assembly of the MOR1D/GRP receptor dimer inhibit morphine-induced scratching but not analgesia. These findings suggest that agonists of MOR1 that are unable to activate the MOR1D/GRP receptor heterodimer may achieve effective analgesia without the side effects of pruritus. A 5-HT1R/ GRP receptor heterodimer similarly facilitates itch transmission in the spinal cord (Zhao et al., 2014c) .
Constitutively Active GPCRs: Pathways to Agonist-Independent Pain and Itch
Given their dynamic nature, it is not surprising that GPCRs can spontaneously adopt active conformations even in the absence of agonists (reviewed in Smit et al., 2007) (Figure 1D ). This constitutive activity increases basal cellular signaling and is sensitive to inhibition by inverse agonists. Inverse agonists have the opposite effects of agonists: whereas agonists activate receptors, inverse agonists inhibit their constitutive activity. One of the earliest descriptions of constitutive activity of GPCRs was the identification of inverse agonists of DOR that inhibited basal GTPase activity of neuroblastoma cells expressing wild-type DOR (Costa and Herz, 1989) . It is now clear that many, if not all, GPCRs can demonstrate constitutive activity and that this activity can be enhanced by receptor mutation or overexpression of G proteins. However, most information about constitutive activity of GPCRs derives from studies of overexpressed receptors in model cell systems. Far less is known about the importance of agonist-independent GPCR signaling for physiological control and mechanisms of disease. 7.1. Structural Basis of Constitutive Activity Studies of mutant GPCRs and homology models have facilitated the identification of multiple domains that may contribute to constitutive activity, particularly in transmembrane regions. However, with the exception of rhodopsin, little is known about the structural basis of constitutive activity, in large part due to the problems associated with crystallizing GPCRs in an activated state. Crystal structures are available for many forms of rhodopsin, including constitutively active forms, and have provided important insights to agonist-induced and constitutive activity (reviewed in Park, 2014) . The constitutive activity of naturally occurring mutants of rhodopsin may underlie vision disorders. 7.2. Constitutive Activity and Pain Although wild-type and mutants of MOR demonstrate constitutive activity, one of the most intriguing findings is that longterm exposure to agonists, such as morphine, can induce a constitutively active form of MOR in cell lines and in vivo (Connor and Traynor, 2010) . Constitutive activity of MOR has been proposed to mediate sustained analgesia by endogenous opioids and to contribute to dependence (Corder et al., 2013) . Intraplantar injection of complete Freund's adjuvant leads to sustained hyperalgesia in mice that resolves over days. This resolution is reversed by centrally acting MOR antagonists and is thus mediated by the central actions of endogenous opioids. The development of analgesia coincides with constitutive activation of MOR within the spinal cord, and intrathecal administration of inverse MOR agonists reinstates the central sensitization of pain and induces signs of opioid withdrawal. Thus, constitutive activity of spinal MOR may contribute to both analgesic signaling of endogenous opioids and the development of tolerance. Although molecular mechanisms responsible for agonist-stimulated constitutive activity of MOR remain to be fully defined, constitutive activity may reflect altered phosphorylation of the activated receptor. However, other mechanisms, such as b-arrestin-2 deficiency, may also contribute to constitutive activity (Walwyn et al., 2007) . Further studies are required to define the molecular and structural basis of GPCR constitutive activity and to determine its importance in the control of physiological and chronic pain.
Compartmentalized Trafficking and Signaling of GPCRs: Pathways to Selectivity
Agonist-evoked endocytosis is a striking demonstration of the dynamic nature of GPCRs. This positional dynamism allows receptors to associate with signaling partners and assemble signalosomes that generate signals in subcellular compartments (reviewed in Irannejad and von Zastrow, 2014; Murphy et al., 2009) (Figure 1E ). Trafficking-dependent compartmentalized signaling may explain how different receptors that couple to the same signaling pathways can selectively control cellular processes. It may also mediate pathological processes and could be a relevant therapeutic target. The inability of antagonists to effectively engage with GPCRs in subcellular compartments, which requires that they traverse several membrane barriers and interact with receptors within multi-protein complexes in acidified endosomes, may sometimes account for their lack of efficacy.
Plasma Membrane Signaling is Tightly Controlled
Ligand degradation/reuptake and receptor desensitization/endocytosis control plasma membrane GPCR signaling ( Figure 5 , step 1). Cell-surface peptidases that degrade neuropeptides can terminate their biological effects ( Figure 5, step 1) . Neprilysin (EC 3.4.24.11) degrades SP, bradykinin, and enkephalins in the extracellular fluid, and mice lacking neprilysin show widespread neurogenic inflammation due to diminished degradation of SP and bradykinin (Sturiale et al., 1999) . Inhibitors of opioid-degrading peptidases have been developed as analgesics. A dual neprilysin and neutral aminopeptidase N (EC 3.4.11.2) inhibitor has anti-nociceptive actions in rodents that are mediated by opioids in the periphery (Bonnard et al., 2015) . These effects may be largely attributable to inhibition of aminopeptidase N since a neprilysin inhibitor would be expected to block degradation of algesic peptides such as SP and bradykinin.
GPCR desensitization also terminates plasma membrane signaling ( Figure 5, step 1) . GPCR kinases (GRKs) phosphorylate activated receptors and thereby enhance their affinity for b-arrestins, which interact with activated receptors and uncouple them from G proteins. Disruption of these mechanisms interferes with nociception, which illustrates their importance for pain transmission. Thus, b-arrestin-2 knockout mice exhibit exacerbated morphine analgesia consistent with compromised MOR desensi- tization (Bohn et al., 1999) . GRK2 heterozygotic mice (50% reduction in GRK2) exhibit sustained inflammatory pain, and selective reduction of GRK2 in Na v 1.8 nociceptors exacerbates hyperalgesia via enhanced sensitization of TRPV1 (Eijkelkamp et al., 2010) . Given that GRK2 is often downregulated in inflammatory conditions, these studies suggest a major role for this kinase in regulating the severity and duration of inflammatory pain.
Anchoring Proteins Organize Painful Signals
Anchoring or scaffolding proteins lack intrinsic enzymatic activity but interact with and organize signaling partners into functional units. In the context of nociception, anchoring proteins are critically important for GPCRdependent activation and sensitization of ion channels (reviewed in Fischer and McNaughton, 2014) .
A Kinase Anchoring Proteins (AKAPs) interact with GPCRs, channels, kinases, phosphatases, GTPases, and phosphodiesterase and can assemble signaling complexes in subcellular domains that are necessary for nociception. Three N-terminal lipid binding domains target AKAP79/150 to membranes, where it assembles an adenylyl cyclase, PKA, PKC, and TRPV1 complex that facilitates bradykinin-and PGE 2 -evoked sensitization of TRPV1 (Efendiev et al., 2013; Jeske et al., 2009; Zhang et al., 2008) . An understanding of the molecular basis of the interactions between AKAP79/150 and TRP channels may enable the development of drugs that disrupt these interactions and suppress pain. Peptides that block AKAP79/150 and TRPV1 interactions suppress hyperalgesia, suggesting therapeutic potential (Fischer et al., 2013) .
Neuron 88, November 18, 2015 ª2015 Elsevier Inc. 643 Neuron Review b-arrestins are promiscuous scaffolding proteins for multiple GPCRs, ion channels and signaling partners. In line with their role in GPCR desensitization, b-arrestins can also desensitize TRPV1. By recruiting phosphodiesterase 4D to TRPV1, b-arrestin-2 suppresses cAMP levels and thereby restricts PKA-dependent activation of TRPV1, which desensitizes the channel (Por et al., 2013) . 8.3. GPCR Trafficking through the Endosomal Network Controls the Duration and Magnitude of Painful Signals Activated GPCRs often traffic to endosomes, an extensive and dynamic tubulo-vesicular network that extends throughout the cytosol ( Figure 5 , steps 2-6). Agonist-evoked endocytosis has been demonstrated for several GPCRs that regulate pain and itch. Painful stimuli evoke NK 1 R endocytosis in second-order neurons of rat spinal cord (Mantyh et al., 1995) . Endogenous opioids and drugs also stimulate endocytosis of MOR and DOR throughout the nervous system (Faget et al., 2012; Poole et al., 2011) . However, there are marked differences in the ability of some agonists to induce endocytosis of the same receptors. Ligand-biased endocytosis is exemplified for MOR and DOR and may explain the capacity of different ligands to evoke tolerance to opioids. Whereas opioid peptides evoke MOR endocytosis, morphine is usually unable to stimulate endocytosis (Williams et al., 2013) . Similarly, although enkephalin and SNC80 strongly stimulate DOR endocytosis, ARM390 has a limited capacity to stimulate DOR internalization (Pradhan et al., 2010) . After chronic administration of SNC80, DOR is downregulated and mice exhibit SNC80 analgesic tolerance that is presumably related to loss of cell-surface receptors. However, chronic administration of ARM390 does not lead to DOR downregulation, although DOR signaling in nociceptive neurons is compromised and mice demonstrate analgesic tolerance. Thus, tolerance can occur by different mechanisms, which depend on the agonist.
The molecular mechanisms of agonist-evoked endocytosis of GPCRs have been extensively studied. By serving as adaptors for clathrin and AP2, b-arrestins mediate endocytosis of many GPCRs. Differences in the affinity of GPCRs for b-arrestins, which depend on the extent of GRK-mediated phosphorylation of intracellular domains (Oakley et al., 2000) , can markedly affect endocytosis. In instances where two or more receptors are simultaneously activated in the same cell, a likely scenario in vivo, competition for b-arrestins may underlie differences in receptor trafficking. By virtue of high-affinity interactions, the NK 1 R sequesters b-arrestins and impedes endocytosis and desensitization of the NK 3 R (Schmidlin et al., 2002) and MOR (Yu et al., 2009) , which display lower-affinity interactions with b-arrestins. The importance of b-arrestin sequestration for pain and itch remains to be determined.
Internalized GPCRs either recycle or are degraded, depending on the receptor and the conditions of stimulation. GPCR recycling is often necessary for the sustained actions of extracellular agonists. One determinant of the rate of recycling is GPCR affinity for b-arrestins (Oakley et al., 1999) . GPCRs that form low-affinity interactions with b-arrestins in endosomes (MOR, NK 3 R) rapidly recycle and resensitize, whereas GPCRs that form high-affinity interactions with b-arrestins in endosomes (NK 1 R) recycle and resensitize slowly (Schmidlin et al., 2003) . Ligand degradation in endosomes also determines the rate of recycling. Endothelin-converting enzyme-1 (ECE-1, EC 3.4.24.71) degrades SP and CGRP in early endosomes, which promotes dissociation of signalosomes, allowing receptors, freed from b-arrestins, to recycle and resensitize Roosterman et al., 2007) (Figure 5 step 5) . ECE-1-dependent recycling allows for sustained inflammatory signaling by SP (Cattaruzza et al., 2009; Jensen et al., 2014) . In a similar manner, ECE-2 degrades certain opioids in early endosomes to promote recycling and resensitization of DOR (Gupta et al., 2014) and MOR (Gupta et al., 2015) . These pathways of GPCR recycling may be physiologically regulated. Thus, SP activation of the NK 1 R in trigeminal neurons promotes MOR recycling and resensitization by a mechanism that involves PKC-mediated phosphorylation of MOR (Bowman et al., 2015) . SP enhances resensitization of fentanyl-stimulated anti-nociception in mice, suggesting the existence of a physiologically relevant crosstalk between GPCRs that mediate inflammatory pain (NK 1 R) and opioid analgesia (MOR). However, recycling is not always required for resensitization. A substantial proportion of activated NK 1 R remains at the cell surface. b-arrestin-1 can recruit protein phosphatase 2A to the non-internalizing receptor, where dephosphorylation mediates resensitization (Murphy et al., 2011) (Figure 5, step 1) .
Some activated GPCRs, including PAR 2 and DOR, traffic to lysosomes after degradation. The mechanisms of lysosomal targeting of GPCRs are not fully understood and vary between receptors. Lysosomal trafficking of PAR 2 requires cCbl-mediated ubiquitination (Jacob et al., 2005) followed by AMSH-and UBPY-mediated deubiquitination in endosomes ). The E3 ligase AIP4 ubiquitinates DOR, which then undergoes AMSH-and UBPY-mediated deubiquitination (Hislop et al., 2009) . A cytoplasmic protein that can bind to the C terminus of DOR, G protein-coupled receptor-associated protein (GASP), also contributes to DOR downregulation (Whistler et al., 2002) . Sustained signaling by agonists of lysosome-targeted GPCRs requires mobilization of stores of intact receptors or new receptor synthesis, but the regulation of plasma membrane trafficking of GPCR from stores has not been examined in detail.
Endosomal Platforms for Sustained GPCR Signals
Originally considered merely a conduit for GPCR recycling or degradation, endosomes are now viewed as a vital site of signaling (Irannejad and von Zastrow, 2014; Murphy et al., 2009) (Figure 5, step 3) . By recruiting GPCRs and components of the mitogen-activated protein kinase cascades to endosomes, b-arrestins can assemble signalosomes that define the location and function of activated kinases (DeFea et al., 2000a (DeFea et al., , 2000b . By degrading SP and disrupting the SP, NK 1 R, b-arrestin, Src signalosome, ECE-1 terminates endosomally mediated ERK1/2 activation Jensen et al., 2014) . The traditional view of G protein-dependent plasma membrane signaling and b-arrestin-dependent and G protein-independent endosomal signaling has been blurred by the appreciation that some GPCRs can signal from endosomes via G proteins (Calebiro et al., 2009; Irannejad et al., 2013) . Very little is known about the contribution of endosomal signaling to pain and itch. However, given that painful stimuli can trigger GPCR endocytosis, it is possible that endosomal signaling contributes to nociception. Indeed, endosomal signaling of the endothelin ETA receptor in dorsal root ganglia neurons mediates the pruritogenic actions of endothelin-1 (Kido-Nakahara et al., 2014) . Whether endosomes are a platform for sustained nociceptive transmission remains to be determined.
Conclusions and Future Perspectives
The realization that GPCRs are dynamic signaling machines, rather than static sentinels of signaling pathways, provides new insights into their physiological functions and reveals novel options for therapeutic intervention. The ability of receptors to adopt distinct conformations upon association with different agonists, signaling partners, or other receptors may explain allosteric modulation, biased agonism, and the functional consequences of receptor oligomerization and constitutive activity. The trafficking of activated receptors to microdomains of plasma and endosomal membranes underlies the generation of signals in subcellular compartments that may account for receptor-specific effects.
Despite important advances, our understanding of the conformational and positional dynamism of GPCRs is incomplete. Most information about the structure of GPCRs derives from studies of antagonist-stabilized receptors. Although conformational changes are thought to explain allosteric modulation, direct experimental evidence showing how binding of an allosteric ligand dynamically alters the conformation of the orthosteric binding site is mostly lacking. The structural basis of biased agonism, by which different agonists are thought to induce receptors to adopt distinct conformations and to couple to divergent signaling pathways, is poorly understood. Similarly, although some antagonist-bound GPCRs crystallize as dimers, the impact of oligomerization on GPCR conformation and precisely how this affects function is not known. Mutational studies have identified domains that are important for constitutive activity of GPCRs, but the structural basis of spontaneous activity is uncertain. Agonist-stimulated trafficking of GPCRs within the endosomal network has been extensively studied, although the mechanisms by which receptors signal from endosomes, and its importance for complex physiological and pathophysiological processes, remains to be defined.
Our understanding of allosteric modulation, biased agonism, oligomerization, constitutive activity, and compartmentalized signaling largely derives from studies of GPCRs in artificial systems. There are major challenges to studying these processes in functionally relevant cells, such as sensory neurons, and in determining their importance for complex physiological and pathophysiological processes, including pain and itch. The efficacy of allosteric modulators in vivo is critically dependent on the tone of the endogenous system, and the differential in vivo actions of various agonists of the same receptor may be explained by altered stability and distribution, rather than biased agonism. Even the apparently simple question of whether two GPCRs are colocalized in membrane microdomains of the same neuron, a prerequisite for their capacity to dimerize, is fraught with controversy. Many GPCRs can become constitutively active after mutation and when overexpressed in cell lines, but the importance of constitutive activity in vivo is less certain. Although it is well established that some GPCRs can robustly internalize in sensory neurons, the importance of this process to pain and itch transmission is unknown, and whether targeting GPCRs in endosomes is an effective therapeutic approach remains to be investigated.
Despite these difficulties, there remains a deep interest in signaling and trafficking of GPCRs. Future developments in our understanding of the conformational and positional dynamism of GPCRs will certainly provide further insights into the operation of these complex signaling machines. The challenge will be to translate these insights into an improved understanding of the integrated and complex processes of pain and itch, and to use this knowledge to inform the development of more selective and effective therapies for these often intractable disorders.
